<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02060292</url>
  </required_header>
  <id_info>
    <org_study_id>3251</org_study_id>
    <nct_id>NCT02060292</nct_id>
  </id_info>
  <brief_title>Novel Vascular Manifestations of Chronic Obstructive Pulmonary Disease</brief_title>
  <acronym>NOVASC COPD</acronym>
  <official_title>Novel Vascular Manifestations of Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>North Bristol NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>North Bristol NHS Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cognitive impairment is a known consequence of cerebral small-vessel disease. Moderate to
      severe cognitive impairment has been shown in up to 60% of certain individuals with COPD and
      is likely to profoundly influence an individual's ability to manage their disease.

      In addition to cerebral small vessel damage and cognitive dysfunction, other organs such as
      the heart, kidneys, and retina are likely to be susceptible to small-vessel damage in COPD.
      Several large population studies have shown that COPD is a significant independent risk
      factor for myocardial infarction, with the effect most marked in early, mild disease.

      We propose to compare non-invasive MR brain imaging of white matter microstructure (diffusion
      tensor), cerebral perfusion (arterial spin labelling) and accumulated cerebral small vessel
      disease (cerebral microbleeds), in COPD patients to smokers without COPD. In addition we plan
      to explore mechanisms of cerebral small vessel disease in COPD by looking for associations
      between arterial stiffness, end organ vascular damage and cognitive function.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Fractional Anisotropy</measure>
    <time_frame>upto 4 weeks</time_frame>
    <description>MRI Diffusion Imaging - measure of cerebral white matter microstructure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Aortic Pulse Wave Velocity</measure>
    <time_frame>upto 4 weeks</time_frame>
    <description>Aortic stiffness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI Cerebral Perfusion - ASL</measure>
    <time_frame>upto 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral Microbleeds</measure>
    <time_frame>upto 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive Function</measure>
    <time_frame>upto 4 weeks</time_frame>
    <description>Montreal Cognitive Assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac MRI</measure>
    <time_frame>upto 4 weeks</time_frame>
    <description>LV &amp; RV Mass</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 % predicted</measure>
    <time_frame>upto 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial Oxygen Saturation</measure>
    <time_frame>upto 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal Photography</measure>
    <time_frame>upto 4 weeks</time_frame>
    <description>Retinal Arterial Narrowing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Micro-albuminuria</measure>
    <time_frame>upto 4 weeks</time_frame>
    <description>Spot urine albumin sample mg/l (milligram albumin per litre of urine)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Status</measure>
    <time_frame>upto 4 weeks</time_frame>
    <description>COPD Assessment Test (CAT score) 0-40</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Serum Inflammatory Markers</measure>
    <time_frame>upto 4 weeks</time_frame>
    <description>Fibrinogen, C reacive Protein, IL-6</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">55</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>COPD</arm_group_label>
    <description>Stable, Non hypoxaemic, without history of vascular disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy smokers</arm_group_label>
    <description>Age matched, smokers without COPD</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Stable COPD
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects must give their signed and dated written informed consent

          2. Subjects must be aged &gt;40 and â‰¤ 85

          3. Subjects with a smoking history &gt; 10 pack years.

          4. COPD group: Subjects with a FEV/FVC &lt;70%

        Exclusion Criteria:

          1. Resting oxygen saturations &lt;92% on room air.

          2. Long term oxygen therapy

          3. Recent exacerbation of COPD (4 weeks)

          4. Ischaemic heart disease

          5. Cerebrovascular disease

          6. Uncontrolled hypertension

          7. Diabetes mellitus

          8. Hepatic failure

          9. Neurological disease

         10. Non-cured tumours

         11. Obstructive sleep apnoea

         12. Current of past alcohol/drug abuse

         13. Known history of dementia

         14. Visual or hearing impairment that precludes neuropsychological assessment

         15. Neuropsychological tests undertaken outside the study

         16. Pregnant women or women who are lactating

         17. Known alpha 1 anti-trypsin deficiency as a cause of their COPD

         18. History of psychiatric disorders, or other conditions that will impact on the validity
             of their consent or interfere with compliance to perform study procedures.

         19. Contra indication to MRI scanning -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James W Dodd, MB ChB PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bristol</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>James W Dodd, MB ChB PhD</last_name>
    <phone>+44 (0)1173238745</phone>
    <email>james.dodd@bris.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>North Bristol NHS Trust</name>
      <address>
        <city>Bristol</city>
        <state>Avon</state>
        <zip>BS10 5NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Warbrick, RN</last_name>
      <email>d.warbrick@nbt.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>James W Dodd, MB ChB PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2013</study_first_submitted>
  <study_first_submitted_qc>February 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2014</study_first_posted>
  <last_update_submitted>August 10, 2015</last_update_submitted>
  <last_update_submitted_qc>August 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Cognitive Function</keyword>
  <keyword>MRI Brain</keyword>
  <keyword>Aortic Stiffness</keyword>
  <keyword>Cerebrovascular disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

